← Back to Search

PET Imaging with 124I-PUH71 for Cancer

Q: What is the current cohort size for this clinical research?

This clinical trial has ceased recruitment, as the last update took place on November 18th 2022. However, individuals with active solid malignancies have 684 trials to select from and those interested in PET Imaging using 124 IPUH71 can partake in 2 different studies.

Q: Are there any particular characteristics that make someone a suitable candidate for this trial?

This clinical trial is recruiting 63 subjects aged between 18 and 90, who suffer from a solid malignancy. Additionally, these patients must adhere to the following criteria: having measurable or evaluable disease (as defined by RECIST), lacking active myeloproliferative neoplasm as confirmed by applicable diagnostic tests, being of childbearing age for females with negative <a href="https://www.withpower.com/clinical-trials/pregnancy">pregnancy</a> test results and/or lack of fertility potential, no <a href="https://www.withpower.com/clinical-trials/breast">breast</a>-feeding; <a href="https://www.withpower.com/clinical-trials/all">all</a> determined through assessment from patient's oncologist and research team members.

Q: Is enrollment for this trial currently open?

This trial has concluded; it was originally posted on December 1st, 2010 and last updated November 18th, 2022. If you are interested in alternative studies, there are 684 clinical trials enrolling patients with solid malignancies and 2 PET Imaging using 124 IPUH71 trials that are presently recruiting participants.

Q: How have PET Imaging with 124 IPUH71 been utilized to explore medical treatments in prior trials?

Currently, there are two clinical trials dedicated to examining the uses of PET Imaging with 124 IPUH71. None of these studies have advanced past Phase 3 yet. A couple of locations in <a href="https://www.withpower.com/clinical-trials/new-york">New york</a> City are hosting research into this method.

Q: Are geriatric individuals being included in the research protocol?

This trial is limited to adults ages 18-90. On the other hand, there are 136 trials available for minors and 621 studies open to those over 65 years old.

Phase < 1

Waitlist Available

Led By Mark Dunphy, DO

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Negative serum pregnancy test for females of childbearing age (11-55 years) and/or lack child-bearing potential

Patients with solid malignancy, myeloproliferative neoplasm, myeloma, and/or lymphoma (histology confirmed by MSKCC Department of Pathology)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial is testing how a new drug, PUH71, reacts in the body and how long it lasts in the blood. The results will help researchers plan how to use PUH71 as a new cancer treatment and if it can be used to detect tumors.

Who is the study for?

This trial is for adults aged 18-90 with certain types of cancer, including solid tumors, myeloma, and lymphomas that can be measured or evaluated. Women must not be pregnant or breastfeeding. Participants should not have had allergic reactions to contrast media, iodide hypersensitivity, hyperthyroidism, significant kidney or liver issues, or acute major illnesses.Check my eligibility

What is being tested?

Researchers are testing a new drug called PUH71 using PET imaging to see how it distributes in the body and tumors and its duration in the blood. This will inform future high-dose trials for cancer treatment and potential use in tumor detection.See study design

What are the potential side effects?

Potential side effects aren't detailed but may include typical reactions related to PET imaging agents such as mild irritation at injection site or allergic reaction due to sensitivity towards iodide-based compounds.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am not pregnant or unable to become pregnant.

Select...

My cancer type has been confirmed by pathology.

Select...

I am between 18 and 90 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To study the pharmacokinetics

Secondary outcome measures

To study the biodistribution

To study the metabolism

To study the radiation dosimetry

Trial Design

1Treatment groups

Experimental Treatment

Group I: PET Imaging Using 124 IPUH71Experimental Treatment1 Intervention

Patients will receive an injection of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71, followed by serial PET scanning and blood draws, over a period of 3 days. Optional with a fourth day of PET scanning is to be pursued, in willing patients.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Samus TherapeuticsUNKNOWN

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,933 Previous Clinical Trials

585,557 Total Patients Enrolled

Mark Dunphy, DOPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Media Library

PET Imaging using 124 IPUH71 Clinical Trial Eligibility Overview. Trial Name: NCT01269593 — Phase < 1

Non-Hodgkin's Lymphoma Research Study Groups: PET Imaging Using 124 IPUH71

Non-Hodgkin's Lymphoma Clinical Trial 2023: PET Imaging using 124 IPUH71 Highlights & Side Effects. Trial Name: NCT01269593 — Phase < 1

PET Imaging using 124 IPUH71 2023 Treatment Timeline for Medical Study. Trial Name: NCT01269593 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current cohort size for this clinical research?

"This clinical trial has ceased recruitment, as the last update took place on November 18th 2022. However, individuals with active solid malignancies have 684 trials to select from and those interested in PET Imaging using 124 IPUH71 can partake in 2 different studies."

Answered by AI

Are there any particular characteristics that make someone a suitable candidate for this trial?

"This clinical trial is recruiting 63 subjects aged between 18 and 90, who suffer from a solid malignancy. Additionally, these patients must adhere to the following criteria: having measurable or evaluable disease (as defined by RECIST), lacking active myeloproliferative neoplasm as confirmed by applicable diagnostic tests, being of childbearing age for females with negative pregnancy test results and/or lack of fertility potential, no breast-feeding; all determined through assessment from patient's oncologist and research team members."

Answered by AI

Is enrollment for this trial currently open?

"This trial has concluded; it was originally posted on December 1st, 2010 and last updated November 18th, 2022. If you are interested in alternative studies, there are 684 clinical trials enrolling patients with solid malignancies and 2 PET Imaging using 124 IPUH71 trials that are presently recruiting participants."

Answered by AI

How have PET Imaging with 124 IPUH71 been utilized to explore medical treatments in prior trials?

"Currently, there are two clinical trials dedicated to examining the uses of PET Imaging with 124 IPUH71. None of these studies have advanced past Phase 3 yet. A couple of locations in New york City are hosting research into this method."

Answered by AI

Are geriatric individuals being included in the research protocol?

"This trial is limited to adults ages 18-90. On the other hand, there are 136 trials available for minors and 621 studies open to those over 65 years old."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

2010. "PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01269593.

All > Aging